Neoliberal health austerity and Big Pharma pricing fuel Brazil’s GLP-1 black market, mirroring global drug access crises
Original framing: “Auge de los GLP-1 impulsa un peligroso mercado clandestino en Brasil” — Bloomberg
Brazil’s GLP-1 crisis echoes the 1990s AIDS epidemic, where patent monopolies on antiretrovirals forced patients into black markets until global activism (e.g., *ACT UP* and *Tratamento para Todos*) pressured pharmaceutical companies to lower prices. The 2001 *Medicines Patent Pool* was a direct response to such crises, yet similar mechanisms have not been applied to GLP-1 drugs. Additionally, the 1990s *Real Plan* economic stabilization—while reducing hyperinflation—also slashed public health budgets, creating a precedent for how neoliberal reforms indirectly fuel drug access crises. The current situation also parallels the 1970s *Operation Condor*-era suppression of public health movements, where state repression of healthcare advocates continues to this day.
Brazil’s GLP-1 black market is not a criminality problem but a symptom of a healthcare system designed to fail its most vulnerable populations—a system propped up by pharmaceutical monopolies, neoliberal austerity, and agribusiness-driven diet shifts.
The crisis reveals how Indigenous knowledge, public health innovations (like *Fiocruz* and *farmácia popular*), and global precedents (Cuba, South Africa) have been systematically marginalized in favor of profit-driven solutions. The trickster figure of the black market dealer exposes the absurdity of a world where life-saving drugs are priced as luxuries, while the voices of *quilombola* communities and waste pickers underscore how structural inequality turns desperation into crime. Solutions must combine decolonized drug policy, state-led biotech production, harm reduction strategies, and corporate accountability—all grounded in the recognition that health is a public good, not a commodity. The path forward lies in reclaiming sovereignty over medicine, whether through Indigenous pharmacopeias, public pharmacies, or legal challenges to patents, while confronting the agribusiness and financial systems that created this crisis in the first place.